This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)

CLINICAL DEVELOPMENT PIPELINE

Regulatory Review

  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase III

  • Nasal Glucagon
    Nasal glucagon is a biologic entity being studied for the treatment of severe hypoglycemia in people with diabetes treated with insulin.

    For more information on nasal glucagon clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-4/18/2017)

     

     
  • Galcanezumab
    LY2951742, (CGRP monoclonal antibody), is a biologic entity that binds and inhibits the activity of calcitonin gene related peptide (CGRP). LY2951742 is being studied for the prevention of both chronic and episodic migraine.

    For more information on galcanezumab clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-4/18/2017)

     
  • Solanezumab (soe" la nez' ue mab)
    LY2062430 (solanezumab) is a biologic entity that binds to soluble monomeric forms of amyloid ß (Ab) after it is produced. LY2062430 is being studied for its potential to slow the progression of Alzheimer's disease.

    For more information on solanezumab clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-4/18/2017)

    None during this time period. 

     
  • Tanezumab (ta nez' oo mab)
    Tanezumab, a biologic entity, is a humanized monoclonal antibody that inhibits nerve growth factor. Tanezumab is being studied in collaboration with Pfizer for the treatment of multiple pain indications including osteoarthritis pain.

    For more information on tanezumab clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-4/18/2017)

    Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab – March 23, 2015

     

     
  • Ixekizumab
    axial spondyloarthritis
    LY2439821 (ixekizumab) is a biologic entity that neutralizes a soluble factor called interleukin-17A (IL-17). LY2439821 is being studied for the treatment of axial spondyloarthritis.

    For more information on ixekizumab clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.




    PRESS RELEASES (1/1/2010-4/18/2017)

    None during this time period.

     
  • Galcanezumab
    LY2951742, (CGRP monoclonal antibody), is a biologic entity that binds and inhibits the activity of calcitonin gene related peptide (CGRP). LY2951742 is being studied for the prevention of cluster headache.

    For more information on galcanezumab clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-4/18/2017)

    None during this time period. 

     
  • Tanezumab (ta nez' oo mab)
    Tanezumab, a biologic entity, is a humanized monoclonal antibody that inhibits nerve growth factor. Tanezumab is being studied in collaboration with Pfizer for the treatment of cancer pain.

    For more information on tanezumab clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-4/18/2017)

    None during this time period.
     
  • Tanezumab (ta nez' oo mab)
    Tanezumab, a biologic entity, is a humanized monoclonal antibody that inhibits nerve growth factor. Tanezumab is being studied in collaboration with Pfizer for the treatment of chronic lower back pain.

    For more information on tanezumab clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-4/18/2017)

    None during this time period.
     
  • Ramucirumab (ra" mue sir' ue mab)
    LY3009806 (ramucirumab), a biologic entity, is an antiangiogenic therapy. Specifically, it is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D. LY3009806 is currently being studied for the treatment of second-line bladder cancer.

    For more information on ramucirumab clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-4/18/2017)

    None during this time period.
     
  • Ramucirumab (ra" mue sir' ue mab)
    LY3009806 (ramucirumab), a biologic entity, is an antiangiogenic therapy. Specifically, it is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D. LY3009806 is currently being studied for the treatment of first-line gastric cancer.

    For more information on ramucirumab clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-4/18/2017)

     
  • Ramucirumab (ra" mue sir' ue mab)
    LY3009806 (ramucirumab), a biologic entity, is an antiangiogenic therapy. Specifically, it is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D. LY3009806 is currently being studied for the treatment of 2nd line hepatocellular carcinoma.

    For more information on ramucirumab clinical studies, click here

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-4/18/2017)

     
  • Ramucirumab (ra" mue sir' ue mab)
    LY3009806 (ramucirumab), a biologic entity, is an antiangiogenic therapy. Specifically, it is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D. LY3009806 is currently being studied for the treatment of first-line, EGFR positive NSCLC.

    For more information on ramucirumab clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



    PRESS RELEASES (1/1/2010-4/18/2017)

     Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer—June 5, 2016


    ASCO Data Underscore Lilly's Diverse Oncology Pipeline And Portfolio
    —May 18, 2016


    Lilly To Present CYRAMZA® (Ramucirumab) Data At 2015 ASCO Annual Meeting—May 28, 2015

    Lilly, Merck Enter Collaboration Agreement To Research Immuno-Oncology Combination Regimens In Multiple Types Of Cancer—January 13, 2015

     

     

     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase II

  • Mirikizumab psoriasis
    LY3074828 (formerly known as IL-23 antibody) is a biologic entity that blocks the activity of the cytokine interleukin 23. LY3074828 is being studied for the treatment of immune diseases including psoriasis.

    For more information on LY3074828 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • PCSK9 Monoclonal Antibody
    LY3015014 (PCSK9 monoclonal antibody) is a biologic entity that binds to and inhibits the activity of proprotein convertase subtilisin/kexin type 9. LY3015014 is being studied for the treatment of cardiovascular disease.

    For more information on LY3015014 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.


     
  • Ultra Rapid Insulin
    LY900014 (LY) is a novel formulation containing locally-acting excipients to accelerate insulin lispro absorption. LY900014 is a biologic entity being studied for the treatment of type 1 and type 2 diabetes

    For more information on LY900014 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • CXCR4 Peptide Antagonist
    LY2510924 (CXCR4 peptide antagonist) is a biologic entity that antagonizes ligand binding to the CXC chemokine receptor 4. LY2510924 is being studied for the treatment of cancer.

    For more information on LY2510924 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  • Emibetuzumab (em” i be tooz’ ue mab)
    LY2875358 (formerly known as c-Met antibody), a biologic entity, was designed as a bivalent c-Met antibody that has neutralization and internalization activity with minimal agonistic activity. LY2875358 is being studied for the treatment of NSCLC.

    For more information on LY2875358 clinical studies, click here.

    NOTE: If you click on the link above it will take you to a site maintained by a third party, which is solely responsible for its content.



     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase I

  • BAFF/IL-17 Bispecific Antibody
    "BAFF/IL-17 Bispecific Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • CXCR1/2 Ligands Antibody
    "CXCR1/2 Ligands Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • IL-21 Antibody
    "IL-21 Antibody" is a new biologic entity being studied for the treatment of immune diseases.

     
  • GIP/GLP-1 Co-agonist Peptide
    "GIP/GLP-1 Co-agonist Peptide" is a new biologic entity being studied for the treatment of diabetes.

     
  • hypoglycemia
    New biologic entity.

     
  • Insulin Basal Long Acting
    "Insulin basal long acting" is a new biologic entity being studied for the treatment of diabetes.

     
  • Insulin-Fc/Dula
    "Basal insulin-Fc + dulaglutide combination" is a new biologic entity being studied for the treatment of diabetes.

     
  • Oxyntomodulin
    "Oxyntomodulin" is a new biologic entity being studied for the treatment of diabetes.

     
  • Aß42 Antibody
    "Aß42 antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • N3pG-Aß Monoclonal Antibody
    "N3pG-Aß Monoclonal Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • Tau Antibody
    "Tau Antibody" is a new biologic entity being studied for the treatment of Alzheimer's disease.

     
  • Angiopoietin 2 MAb cancer
    "Angiopoietin 2 Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • CSF-1R Monoclonal Antibody
    "CSF-1R Monoclonal Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  • FGFR3-ADC
    "FGFR3-ADC" is a new biologic entity being studied for the treatment of cancer.

     
  • PD-L1 Antibody
    "PD-L1 Antibody" is a new biologic entity being studied for the treatment of cancer.

     
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of April 18, 2017. Lilly assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.
  • Select NILEX
  • Diagnostic
GTM-PQNKVL